CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Macromolecule-Loaded Hybrid Extracellular Vesicles via Ionic Lipid-Based Post-Loading for Intracellular Delivery: Functional Evaluation for Neurodegenerative Therapy.
细胞外囊泡(EVs)作为天然载体,展现出作为药物递送系统(DDS)的前景。
细胞外囊泡(EVs)作为天然载体,在药物递送系统(DDS)中展现出前景。我们利用专有的离子脂质基质(ILB),开发了一种非侵入性后加载方法,通过静电驱动杂交将大分子封装到EVs中,而不破坏EV结构。使用从牛乳和脂肪细胞来源间充质干细胞培养基中分离的EVs,以可重复的方式制备了封装蛋白质或核酸分子用于递送的不同ILB含量的杂交EVs(H-EV)。制备后,H-EV保留了与天然EVs相当的EV表面标志物。细胞摄取后,封装的分子从内体逃逸到细胞质中并表现出预期功能。在使用诱导了α-突触核蛋白(α-Syn)聚集的SH-SY5Y神经母细胞瘤细胞的实验中,导入封装抗α-Syn抗体(Abs)的H-EV显著抑制了α-Syn聚集。此外,使用H-EV递送抗磷酸化AKT Abs促进了caspase 3/7活性和细胞凋亡。静脉内给予小鼠封装模型Ab的H-EV后,通过离体成像评估,在24小时内可在脑皮质、小脑、海马和与神经退行性疾病相关的其他细胞中检测到Ab信号。H-EV能够加载多种分子并将其靶向运输到特定器官和细胞质,突显了其作为针对细胞内蛋白质的Ab疗法的多功能平台的潜力。
Extracellular vesicles (EVs) are natural carriers that show promise as drug delivery systems (DDS). We developed a non-invasive post-loading method to encapsulate macromolecules in EVs using our proprietary ionic lipid base (ILB), which enables electrostatically driver hybridisation without disrupting EV structure. Using EVs isolated from bovine milk and adipocyte-derived mesenchymal stem cell culture medium, hybrid-EVs (H-EV) with different ILB contents encapsulating protein or nucleic acid molecules for delivery were produced in a reproducible manner. The H-EV retained EV surface markers comparable to those of native EVs after preparation. After cellular uptake, the encapsulated molecules escaped from endosomes into the cytoplasm and exhibited intended functions. In an experiment using SH-SY5Y neuroblastoma cells in which -synuclein ( Syn) aggregation was induced, the introduction of H-EV encapsulating anti- Syn antibodies (Abs) significantly suppressed Syn aggregation. Furthermore, delivery of anti-phospho-AKT Abs using H-EV promoted caspase 3/7 activity and cell apoptosis. Intravenous administration of H-EV encapsulating a model Ab into mice resulted in detectable Ab signals in the cerebral cortex, cerebellum, hippocampus and other cells associated with neurodegenerative diseases within 24 h, as assessed by ex vivo imaging. H-EV enabled loading of various molecules and their targeted transport to specific organs and the cytoplasm, highlighting their potential as a versatile platform for Ab therapies targeting intracellular proteins.
MEMBER ACCOUNT
登录成功会直接打开下一页。